- BGI Publishes Largest Ever Genomic Study of Chinese Population Discoveries in more than 140,000 Genomes throughout China
- BGI, NOAA Fisheries, and The Nature Conservancy Announce Partnership to Help Endangered Orcas
- BGI Signs Memorandum of Understanding with The University of Michigan
- China National GeneBank Signs a Colleboration Agreement with Queensland University on Scientific Research
- Establishment of the first Macaca fascicularis gut microbiome gene catalog
- Establishing the first gene catalogue of Sprague-Dawley rat gut metagenome based on the BGISEQ-500 platform
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Meet The Chinese Company That Wants To Be The Intel Of Personalized Medicine
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
Tel: +86-755-36307212Email: email@example.com
May 16, 2016, Shenzhen, China – BGI, the world’s largest omics organization, has signed a partnership agreement with Singapore-based oncology research and diagnostics company Clearbridge BioMedics (CBB). This collaboration aims to bring the CTC (circulating tumor cell) liquid biopsy into the market in Mainland China, Hong Kong and Macao. BGI will work together with CBB to solely distribute and market the ClearCell® FX1 solution and related products in China, extend this technology into clinical and cutting-edge research applications, and develop clinical products. The ClearCell® technology is a label-free, automated system that is able to isolate and enrich intact, viable rare cells from a patient’s blood sample.
It aims to develop an integrated CTC liquid biopsy solution by leveraging BGI’s strengths from genomics to trans-omics and CBB’s expertise in rare cell separation, in order to provide more actionable clinical insights through a simple blood draw.
The project focuses on major types of cancer in China, such as lung, breast, and liver. BGI and CBB will collaborate to drive clinical adoption by working with experts in leading hospitals in order to promote the CTC technology and genomic applications. Possible applications include cancer-related targeted gene analysis, drug-related gene analysis, single cell analysis and cancer immunotherapy.
“We believe that liquid biopsy plays a key role in clinical diagnostics and personalized medicine and can potentially even aid in immunotherapy PD-L1 treatment management. BGI is a global leader in genomics and precision medicine space, and this collaboration supports our efforts to bring our ClearCell® FX1 System into the China research and clinical markets. We are convinced their strong network, track record and excellent capabilities complement our execution and align with our strategic vision for China,” said Mr Johnson Chen, Chairman and Founder of Clearbridge BioMedics.
“BGI’s goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating an array of leading technologies. This includes BGISEQ series sequencers for genomics, economies of scale for sample storage and bioinformatics for IT and computing resources. Liquid biopsy, a critical cancer sample format which enables access to extremely rare cells such as CTC, will enable us to study cancer genomics and diseases at the single cell level. Having worked closely with Clearbridge BioMedics for the last few years, we are very confident that the combination of their rare cell enrichment technology with BGI’s genomic and trans-omics platform, and our strong collaboration networks, will result in better cancer management. We dedicate to accelerating the adoption of precision medicine in China, to better serving the needs of patients,” said Dr. Xun Xu, Executive Vice President of BGI and Director of BGI Research.
About Clearbridge BioMedics
Clearbridge BioMedics is a clinical stage oncology research and diagnostics company that enables real-time liquid biopsy using a label-free rare-cell CTC enrichment platform. It is a National University of Singapore (NUS) spin-off company that is committed to revolutionizing cancer diagnostics and patient care. The ClearCell® FX1 System, using the CTChip®, is based on novel microfluidics technology that effectively isolates intact and viable CTCs from patients’ blood. The system uses Dean flow fractionation for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells that could be used for cancer screening, diagnosis, staging, personalized medicine and treatment monitoring. Utilizing the next generation non-invasive liquid biopsy to analyze blood samples for CTCs, the device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of precision medicine.
Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. The company has won numerous awards and garnered global recognition for the ClearCell® FX System. Clearbridge BioMedics attained ISO 13485 certification in 2011.
Chan Yiu Lin (Ms)
Greener Grass Communications
Mobile: (+65) 9765 5897
Gwendolene Yeo (Ms)
Business Development Director
Mobile: (+65) 8699 9291
Luting Song (Mr)
Mobile: (+86) 183 2074 7285
Bicheng Yang, Ph.D. (Ms)
Public Communication Officer